Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 29, 2024

Response-Guided Neoadjuvant Sacituzumab Govitecan Therapy for Localized TNBC

Annals of Oncology

 

Additional Info

Annals of Oncology
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
Ann. Oncol 2024 Mar 01;35(3)293-301, LM Spring, SM Tolaney, G Fell, V Bossuyt, RO Abelman, B Wu, S Maheswaran, L Trippa, A Comander, T Mulvey, S McLaughlin, P Ryan, L Ryan, E Abraham, A Rosenstock, AC Garrido-Castro, F Lynce, B Moy, SJ Isakoff, N Tung, EA Mittendorf, LW Ellisen, A Bardia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading